EdgeScore

SLDB · Nasdaq

Solid Biosciences Inc.: financial statements

Financially weak · see the checkFigures in USD, fiscal years

Revenue and net income

Revenue 2017: $0Net income 2017: -$52.1M2017Revenue 2018: $0Net income 2018: -$74.8M2018Revenue 2019: $0Net income 2019: -$117M2019Revenue 2020: $0Net income 2020: -$88.3M2020Revenue 2021: $13.6MNet income 2021: -$72.2M2021Revenue 2022: $8.1MNet income 2022: -$86.0M2022
RevenueNet income

Operating and free cash flow

Operating cash flow 2017: -$43.2MFree cash flow 2017: -$45.5M2017Operating cash flow 2018: -$70.2MFree cash flow 2018: -$78.0M2018Operating cash flow 2019: -$92.7MFree cash flow 2019: -$97.1M2019Operating cash flow 2020: -$56.6MFree cash flow 2020: -$57.5M2020Operating cash flow 2021: -$77.8MFree cash flow 2021: -$79.0M2021Operating cash flow 2022: -$98.0MFree cash flow 2022: -$101M2022
Operating cash flowFree cash flow

Margins

Operating 2021: -530.5%Operating 2022: -1315.2%Net 2021: -530.0%Net 2022: -1062.3%201720182019202020212022
GrossOperatingNet

Returns

ROE 2018: -59.8%ROE 2019: -146.4%ROE 2020: -66.8%ROE 2021: -34.7%ROE 2022: -40.6%ROIC 2019: -440.2%ROIC 2021: -171.9%ROIC 2022: -115.7%ROA 2017: -68.4%ROA 2018: -53.6%ROA 2019: -113.3%ROA 2020: -51.6%ROA 2021: -31.1%ROA 2022: -33.0%201720182019202020212022
ROEROICROA

Income statement

USD201720182019202020212022Last year
Revenue$0$0$0$0$13.6M$8.1M-41%
Operating income-$54.9M-$75.7M-$119M-$88.4M-$72.3M-$106M-47%
EBITDA-$54.4M-$74.1M-$116M-$84.5M-$69.3M-$104M-50%
Income tax—$0$0$0$0$0
Net income-$52.1M-$74.8M-$117M-$88.3M-$72.2M-$86.0M-19%

Cash flow

USD201720182019202020212022Last year
Operating cash flow-$43.2M-$70.2M-$92.7M-$56.6M-$77.8M-$98.0M-26%
Capital expenditure$2.3M$7.8M$4.4M$899K$1.3M$3.0M+135%
Free cash flow-$45.5M-$78.0M-$97.1M-$57.5M-$79.0M-$101M-28%
Depreciation & amortization$448K$1.6M$2.8M$3.9M$3.0M$2.4M-19%

Balance sheet

USD201720182019202020212022Last year
Cash$52.1M$86.4M$76.0M$155M$119M$155M+30%
Current assets$70.7M$129M$86.3M$159M$223M$220M-1%
Total assets$76.2M$140M$103M$171M$232M$260M+12%
Current liabilities$11.3M$12.5M$18.3M$24.5M$23.6M$22.5M-5%
Total liabilities$11.3M$14.4M$23.4M$39.1M$24.2M$48.6M+101%
Shareholders' equity-$59.3M$125M$80.0M$132M$208M$212M+2%
Net debt-$52.1M-$86.4M-$76.0M-$155M-$119M-$155M-30%

Ratios

201720182019202020212022Last year
Operating margin————-530.5%-1315.2%
Net margin————-530.0%-1062.3%
Return on equity—-59.8%-146.4%-66.8%-34.7%-40.6%
Return on assets-68.4%-53.6%-113.3%-51.6%-31.1%-33.0%
Return on invested capital——-440.2%—-171.9%-115.7%
Current ratio6.2710.314.726.499.439.76
Quick ratio6.2710.314.726.499.439.76

Data source: SEC EDGAR, company annual reports. Lines a company does not report are left empty. Free cash flow is operating cash flow minus capital expenditure. Ratios use the same formulas as the EdgeScore check.

For information and education only. Not investment advice. Data may contain errors.